Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis

Table 4 Absolute numbers of B cells in bone marrow (per 10⁶ mononuclear cells)

	CD38+IgD- (Bm5)		CD38+IgD+ (Mature Bm2)		CD38++IgD- (Immature/T1)		CD38++IgD+ (Immature/T1)		CD38+++IgD- (Plasma blasts)
	N = 10	n = 14	n = 10	n = 14	n = 10	n = 14	n = 10	n = 14	n = 10	n = 14
Baseline
Day 0	34 ± 32	55 ± 51	140 ± 135	203 ± 140	96 ± 98	180 ± 289	19 ± 15	35 ± 49	27 ± 16	38 ± 31
Short-term
1 month	2 ± 2 P = 0.01		0.9 ± 1 P = 0.01		48 ± 71 P = ns		9 ± 25 P = ns		21 ± 19 P = ns
3 months		12 ± 32 P = 0.04		1 ± 2 P = 0.0001		86 ± 97 P = ns		3 ± 5 P = 0.03		23 ± 29 P = ns
Post-RTX survival %	6	22	1	0.5	50	48	47	9	78	61

* Values are given as mean ± standard deviation.
** Statistics are calculated with paired T-test, P-values are given in comparison to day 0.
RTX = rituximab.

ISSN: 1478-6362